People without spouses under-represented in Alzheimer's clinical trials

December 19, 2012

MINNEAPOLIS - A new study suggests that people without a spouse are represented less in Alzheimer's disease clinical trials compared to people with spouses. The study is published in the December 19, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"Nationwide, half of all unpaid Alzheimer's disease caregivers are under the age of 50 and as many as 68 percent are the children, children-in-law or grandchildren of these patients," said study author Joshua D. Grill, PhD, Assistant Professor of Neurology at the UCLA Mary S. Easton Center for Alzheimer's Disease Research and a member of the American Academy of Neurology. "In contrast, in our analyses, 67 percent of the 2,041 Alzheimer's clinical trial participants had a spouse as their study partner. We found that there were several differences between people with spouse and adult child study partners that could affect the results of the trials and interpretations of those results."

Grill adds that factors such as race and caregiver attitude may also impact recruitment to trials. For example, only five percent of participants across the trials were Hispanic and those with an adult child study partner were twice as likely as those with spouse partners to be Hispanic. In addition, six percent of participants were African-American and those with adult child study partners were nearly three times as likely to be African-American as those with spouse study partners.

For the study, the research team categorized people with Alzheimer's disease based on the type of study partner they had - either spouse, adult child or other study partners - from six clinical trials conducted by the Alzheimer's Disease Cooperative Study.

In addition to the differences in enrollment, they found that participants with other study partners were at increased risk to drop out of studies.

After considering other factors, the risk of dropout for "other" study partner group was 70 percent higher than that for the "spouse" study partner group.
-end-
The study was supported by the National Institute on Aging, the Sidell-Kagan Foundation and the Marian S. Ware Alzheimer Program.

To learn more about Alzheimer's disease, visit http://www.aan.com/patients.

The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

Media Contacts:
Rachel Seroka, rseroka@aan.com, (612) 928-6129
Angela Babb, APR, ababb@aan.com, (612) 928-6102

American Academy of Neurology

Related Neurology Articles from Brightsurf:

Lancet Neurology publishes results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's
AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology

Telemedicine effective for monitoring patients in large pediatric neurology network
As the COVID-19 pandemic sent entire communities into lockdown, doctors quickly adopted telehealth strategies without knowing whether they would be effective or feasible.

The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases
A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

Meaningful change in culture urged to save neurology, reduce gender gap
UC Davis School of Medicine dean, NINDS deputy director lead national charge to improve conditions for women in neurology.

BrainStorm Cell Tx publishes NurOwn ALS Phase 2 randomized trial data in neurology
Results from Brainstorm Cell Therapeutic's NurOwn randomized Phase 2 clinical trial were published in Neurology.

The Lancet Neurology: Pioneering study suggests that an exoskeleton for tetraplegia could be feasible
A whole-body exoskeleton, operated by recording and decoding brain signals, has helped a tetraplegic patient to move all four of his paralysed limbs, according to results of a 2-year trial published in The Lancet Neurology journal.

The Lancet Neurology: Frailty could make people more susceptible to dementia
New research published in The Lancet Neurology journal suggests that frailty makes older adults more susceptible to Alzheimer's dementia, and moderates the effects of dementia-related brain changes on dementia symptoms.

The Lancet Neurology: Cannabis-based drug in combination with other anti-spasticity
Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs.

New neurology studies a 'wakeup call' for global health
Neurology experts from around the world will convene Nov. 27 in New Zealand for a Global Brain Summit examining what one calls 'the greatest challenge of societies in the 21st century.' Among the neurological disorders to be discussed at the Summit are stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and migraine and other headaches.

The Lancet Neurology: Daily and weekly cycles of epileptic seizures more common than previously thought
Understanding the pattern of seizures, and how they are linked to circadian rhythms, could be important in improving management of epilepsy.

Read More: Neurology News and Neurology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.